



[Home](#) / [Investors](#) / [News Releases](#)

# Insmmed Reports Financial Results for Second Quarter and First Half of 2007

RICHMOND, Va., Aug 02, 2007 (BUSINESS WIRE) --

Insmmed Inc. (Nasdaq:INSM), (referred to herein as "Insmmed", "we", "our" and "us"), a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs, today announced results for the second quarter and six-month period ended June 30, 2007.

Revenues for the three months ended June 30, 2007 were \$2.3 million, up from \$210,000 from the corresponding period in 2006. The increase was due to two factors: improvements in cost recovery from Insmmed's Expanded Access Program (EAP) to treat patients with amyotrophic lateral sclerosis (ALS) and the receipt of licensing income from our January 2007 agreement with NAPO Pharmaceuticals Inc.

The net loss for the second quarter of 2007 was \$2.5 million, or \$0.02 per share, compared with a net loss of \$8.9 million, or \$0.09 per share, in the second quarter of 2006. The year-over-year improvement was due mainly to a reduction in selling, general and administrative (SG&A) expenses, which fell to \$1.2 million from \$5.2 million in the second quarter of 2006, and to a drop in research and development (R&D) expenses to \$3.7 million from \$4.3 million. The reduction in SG&A was due primarily to reduced litigation expenses and the elimination of commercial expenses associated with our business restructuring plan. The drop in R&D expenses reflected a reduction in our clinical and commercial manufacturing activity. Interest income in the second quarter of 2007 fell to \$224,000 from \$577,000 a year earlier. This was due to a lower average cash balance on hand for the most recent quarter.

For the six months ended June 30, 2007, revenues totaled \$3.9 million, up from \$263,000 in the first six months of 2006. Consistent with second quarter results, the increase was due to improvements in the cost recovery from our EAP and the receipt of licensing income from our agreement with NAPO Pharmaceuticals, together with increased sales of our lead drug IPLEX(TM).

The net loss for the six months ended June 30, 2007 was \$12.8 million, or \$0.12 per share, compared to \$22.3 million, or \$0.25 per share, for first six months of 2006. Year-over-year, R&D expenses dropped to \$9.8 million for the first half of 2007, from \$11.5 million, reflecting lower litigation expenses, which were included in R&D during the first quarter of 2006, and reduced clinical and commercial manufacturing activity. SG&A expenses fell to \$6.5 million for the first half of 2007 from \$9.0 million a year earlier, due to a combination of reduced litigation expenses and the elimination of commercial expenses. This reduction was partially offset by severance costs associated with our business restructuring plan.

Interest income for the first half of 2007 was \$525,000, compared to \$889,000 for the first half of 2006. Interest expense for the six months ended June 30, 2007 was \$306,000, compared to \$3.0 million for the first half of 2006. The decrease in interest expense resulted from lower amortization of the debt discount associated with our March 2005 financing, as an acceleration of the discount took place in the first quarter of 2006 due to the conversion of notes into shares of Insmmed common stock.

As of June 30, 2007, Insmmed had total cash and cash equivalents on hand of \$22.3 million, compared to \$24.1 million on hand as of December 31, 2006. The \$1.9 million decrease in cash and cash equivalents reflected the use of \$18.7 million for operating activities and \$500,000 utilized for the Company's investment in NAPO Pharmaceuticals Inc. The decrease was partially offset by net proceeds of \$17.0 million from an offering of our common stock and warrants to purchase common stock and \$300,000 from a reduced letter of credit.

## Second Quarter Financing Activities

On May 4, 2007, Insmmed sold 20,255,367 shares of its common stock together with warrants to purchase up to 2,025,536 shares of its common stock. The price to the investors was \$0.90 per unit, which was comprised of one share of common stock and a warrant to purchase 0.1 share of common stock. The units were not issued or

certificated, and the shares of common stock and warrants were immediately separable and issued separately. The warrants may be exercised between November 3, 2007 and May 3, 2012 and have an exercise price of \$1.10 per share. The offering was made pursuant to the Company's effective shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission. Net proceeds to the Company from the offering were \$17.0 million.

#### Insmed Expected to Launch into Follow-On Biologics Market

"Our latest results clearly show not only an improving financial picture but, perhaps more importantly, that Insmed is successfully preparing for its launch into a substantial new market in follow-on biologics, said Insmed President and CEO Geoffrey Allan, Ph.D.

"We believe that Congress will soon pass legislation allowing the marketing of 'biogenerics', medicines similar to major protein-based drugs going off-patent. If and when this legislation passes, we believe our state-of-the-art manufacturing facility and drug-development expertise should place us in an advantageous position to rapidly capture a portion of this substantial opportunity. In the meantime, our second quarter financials indicate that Insmed has reduced its expense levels, gained a solid revenue stream from its EAP and has decreased its burn rate," concluded Dr. Allan.

#### Investor Conference Call

Insmed will host a conference call on Thursday, August 2, 2007 at 11:00 a.m. Eastern Time to discuss the financial results for the first six months ended June 30, 2007, and to provide a business update.

Individuals interested in listening to the live call may do so by dialing 877-407-0782 toll free within the United States and Canada, or 201-689-8567 for international callers.

A telephonic replay of the call will be available approximately two hours after the call for a period of two weeks at 877-660-6853 from the United States and 201-612-7415, for international callers. The account # is 286 and conference id # 249996.

Individuals interested in listening to the conference call via the Internet may do so by visiting Insmed's website at [www.insmed.com](http://www.insmed.com). A replay of the call will be available on the website for a period of 90 days.

#### About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit [www.insmed.com](http://www.insmed.com). To be added to Insmed's investor lists, please contact Haris Tajyar at [htajyar@irintl.com](mailto:htajyar@irintl.com) or at 818-382-9702.

#### Forward Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow on biologics market may be unsuccessful, our common stock could be delisted from the Nasdaq Global Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

